Genrix (shanghai) Biopharmaceutical Co., Ltd.

This early-stage clinical trial is testing a new injection called GR1803 in people with systemic lupus erythematosus (lupus). The study aims to see if the treatment is safe and if it helps control lupus symptoms. Researchers will enroll 44 participants who have active lupus despi…

This study is testing whether an experimental injection called GR1802, when added to a person's usual allergy medicines, can better control the sneezing, runny nose, and itchy eyes caused by seasonal allergies. It will involve 150 adults whose symptoms are not well-controlled by …

This is an early safety study testing a new injection called GR2303 in healthy volunteers. Researchers will give 64 participants either the drug or a placebo (inactive substance) to see how the body handles it and check for side effects. The main goal is to understand if GR2303 i…